Clinical trials: Advanced Non-squamous Non-small-cell Lung Cancer
Metastatic Solid Tumor, Advanced Solid Tumor
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
The main purpose of this study is to find out whether the study drug, LY4050784, is safe, tolerable and effective in participants alone or in combination with other anticancer agents.
- Conditions
- Metastatic Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, SMARCA4-Deficient Tumor
- Trial name
- NCT06561685
- Testing
- LY4050784, Pembrolizumab, Cisplatin
- Where
- 33 sites in United States, France and 4 more
- Volunteers
- 340 people
- Sponsor
- Eli Lilly and Company
Non-Small Cell Lung Cancer
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
This is a global, multicenter, open-label study that aims to assess the efficacy and safety of zelenectide pevedotin in participants with previously treated NECTIN4-amplified advanced or metastatic non-small cell lung cancer…
- Trial name
- NCT06933329
- Testing
- Zelenectide pevedotin
- Where
- 3 sites in France, Spain
- Volunteers
- 73 people
- Sponsor
- BicycleTx Limited
Non-small Cell Lung Cancer
REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer
The primary objective of the study is to compare the progression-free survival (PFS) of REGN2810 (cemiplimab) plus ipilimumab combination therapy (hereinafter referred to as REGN2810/ipi) and REGN2810 plus 2 cycles only of…
- Trial name
- NCT03515629
- Testing
- REGN2810/ipi, REGN2810/chemo/ipi, Pembrolizumab
- Where
- 3 sites in United States, Italy and 1 more
- Volunteers
- 5 people
- Sponsor
- Regeneron Pharmaceuticals
Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8
Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer
This phase III trial studies whether pembrolizumab alone as a first-line treatment, followed by pemetrexed and carboplatin with or without pembrolizumab after disease progression is superior to induction with pembrolizumab…
- Conditions
- Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
- Trial name
- NCT03793179
- Testing
- Biospecimen Collection, Carboplatin, Computed Tomography
- Where
- 1,094 sites in United States, Canada and 1 more
- Volunteers
- 600 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumor, Non-small Cell Lung Cancer
A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors
This study is evaluating the safety, side effects, how the body processes HH160, and its early anticancer activity when given alone or with other cancer treatments in participants with advanced solid tumors.
- Conditions
- Solid Tumor, Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Colorectal Cancer
- Trial name
- NCT07623369
- Testing
- HH160
- Where
- 3 sites in Australia, China
- Volunteers
- 299 people
- Sponsor
- Huahui Health
Non Small Cell Lung Cancer
A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung.
- Trial name
- NCT05513703
- Testing
- Telisotuzumab Vedotin
- Where
- 29 sites in United States, Australia and 7 more
- Volunteers
- 9 people
- Sponsor
- AbbVie
EGFR Mutation Positive Advanced Non Small Cell Lung Cancer, PD-L1 Positive
A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC.
A prospective, controlled Phase II clinical study on the efficacy and safety of the combination of limertinib and bevacizumab versus limertinib monotherapy as first - line treatment for locally advanced or recurrent metastatic…
- Trial name
- LIBRA (NCT06982924)
- Testing
- Limertinib+bevacizumab, Limertinib
- Volunteers
- 136 people
- Sponsor
- Shanghai Chest Hospital
Advanced Solid Tumors, Colorectal Cancer
Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment
This study is a Phase 1 and pharmacologic open-labeled dose-escalation trial using a "3+3" design, evaluating MM-151 at varying dose levels and frequencies, and subsequently in combination with irinotecan.
- Conditions
- Advanced Solid Tumors, Colorectal Cancer, Squamous Cell Head and Neck Cancer, Non Small Cell Lung Cancer
- Trial name
- NCT01520389
- Testing
- MM-151, MM-151 + irinotecan
- Where
- 4 sites in United States
- Volunteers
- 112 people
- Sponsor
- Merrimack Pharmaceuticals
Metastatic Breast Cancer, Advanced Non-Small Cell Squamous Lung Cancer
HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease
The goal of this phase II clinical trial] is to analyze the efficacy of patritumab deruxtecan (HER3-DXd) in patients with metastatic breast cancer (MBC) or advanced non-small cell lung cancer (aNSCLC) with active brain metastases…
- Conditions
- Metastatic Breast Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Solid Tumor, Adult
- Trial name
- TUXEDO-3 (NCT05865990)
- Testing
- Patritumab deruxtecan
- Where
- 8 sites in Austria, Spain
- Volunteers
- 63 people
- Sponsor
- MedSIR
Non-Small Cell Lung Carcinoma, Advanced Non-Small Cell Squamous Lung Cancer
Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT
Activity of patritumab deruxtecan (U3-1402; HER3-DXd) has been shown in a phase I/II study in patients with HER3 expressing breast cancer as well as in a phase I study in patients with EGFR TKI refractory EGFR mutation positive…
- Conditions
- Non-Small Cell Lung Carcinoma, Advanced Non-Small Cell Squamous Lung Cancer, EGFR Gene Mutation
- Trial name
- NCT06222489
- Testing
- 89Zr-Patritumab deruxtecan
- Where
- Netherlands
- Volunteers
- 16 people
- Sponsor
- The Netherlands Cancer Institute
Advanced Non-squamous Non-small-cell Lung Cancer, Recurrent Non-Squamous Non-Small Cell Lung Cancer
Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients
The goal of this clinical trial is to evaluate the efficacy and safety of albumin-bound paclitaxel-lenvatinib-pembrolizumab in advanced nonsquamous NSCLC patients after progression to first-line anti-PD-1/L1 inhibitor with…
- Conditions
- Advanced Non-squamous Non-small-cell Lung Cancer, Recurrent Non-Squamous Non-Small Cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer
- Trial name
- NCT06028633
- Testing
- pembrolizumab, lenvatinib, albumin-bound paclitaxel
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Peking University First Hospital
Non-Squamous Non-Small Cell Lung Cancer
Study of Paclitaxel/Carboplatin With or Without Bavituximab in Previously Untreated Non Small-Cell Lung Cancer
This is a randomized, open-label, multicenter, phase 2 study comparing Paclitaxel/Carboplatin with or without bavituximab in patients that have previously untreated locally advanced or metastatic non-small cell lung cancer…
- Trial name
- NCT01160601
- Testing
- Paclitaxel / Carboplatin, bavituximab
- Where
- 40 sites in United States, Georgia and 3 more
- Volunteers
- 86 people
- Sponsor
- Peregrine Pharmaceuticals
Locally Advanced or Metastatic Solid Tumours
A Study to Evaluate Safety and Efficacy of Multiple Dosing With VB10.NEO and Bempegaldesleukin (NKTR-214) Immunotherapy in Patients With Locally Advanced or Metastatic Cancer
This open labelled first in human dose phase 1/2a study is designed to evaluate safety, feasibility and efficacy of multiple dosing with individualised VB10.NEO and bempegaldesleukin (NKTR-214) immunotherapy in patients with…
- Trial name
- DIRECT-01 (NCT03548467)
- Testing
- VB10.NEO, Bempegaldesleukin
- Where
- 6 sites in Germany
- Volunteers
- 41 people
- Sponsor
- Nykode Therapeutics ASA
Cancers Harbouring an EGFR Mutation, (Excluding Non-squamous Non- Small Cell Lung Cancer, a Registered Indication), a HER2 Mutation or a HER3 Mutation
An Explorative Study of Afatinib in the Treatment of Advanced Cancer Carrying an EGFR, a HER2 or a HER3 Mutation
Objective(s):To investigate the efficacy and safety of afatinib in EGFR, HER 2 and HER3 mutated cancers, regardless of cancer type, excluding EGFR mutated non-small cell lung cancer.
- Trial name
- NCT03810872
- Testing
- Afatinib, Paclitaxel
- Where
- 5 sites in Belgium
- Volunteers
- 87 people
- Sponsor
- Universitair Ziekenhuis Brussel
Double Blind
SCTB41 Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer
This is a multicenter Phase II/III study evaluating the efficacy and safety of SCTB41 combined with chemotherapy versus tislelizumab combined with chemotherapy as first-line treatment in patients with driver-negative locally…
- Trial name
- NCT07662395
- Testing
- SCTB41, Tislelizumab, Paclitaxel
- Where
- China
- Volunteers
- 410 people
- Sponsor
- Sinocelltech Ltd.
Non Small Cell Lung Cancer
Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC
Evaluate the efficacy and safety of Anlotinib plus Icotinib as the first-line treatment in patients with sensitive EGFR mutations advanced non-small cell lung cancer.
- Trial name
- ALTER-L004 (NCT03736837)
- Testing
- Anlotinib Plus Icotinib
- Where
- 5 sites in China
- Volunteers
- 60 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Advanced Squamous Non Small Cell Lung Cancer
AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer
This trial is a Phase III study. All patients are stage IIIB/C (unsuitable for radical therapy) or stage IV squamous non-small cell lung cancer(NSCLC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
- Trial name
- NCT05840016
- Testing
- AK112, Carboplatin, Paxlitaxel, Tislelizumab, Carboplatin, Paxlitaxel
- Where
- China
- Volunteers
- 532 people
- Sponsor
- Akeso
Non-small-cell Lung Cancer
Study of Bavituximab Plus Docetaxel in Patients With Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer
The primary purpose of this research study is to see whether adding bavituximab (an investigational drug) to the standard chemotherapy drug docetaxel, will improve the results of the treatment for non-small-cell lung cancer.
- Trial name
- NCT01138163
- Where
- 53 sites in United States, Georgia and 3 more
- Volunteers
- 121 people
- Sponsor
- Peregrine Pharmaceuticals
Non-Squamous Non-Small Cell Lung Cancer
A Study on the Correlation Between Tarceva (Erlotinib) - Induced Rash and Efficacy in EGFR Mutated Participants With Advanced Non-Small Cell Lung Cancer Receiving First-Line Therapy
This open-label, single arm study will assess the correlation between Tarceva (erlotinib)-induced rash and efficacy in participants with inoperable, locally advanced, recurrent or metastatic non-small cell lung cancer (NSCLC)…
- Trial name
- NCT01174563
- Testing
- erlotinib [Tarceva]
- Where
- 16 sites in Israel
- Volunteers
- 60 people
- Sponsor
- Hoffmann-La Roche
Metastatic NSCLC, Recurrent NSCLC
Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC
This is a single-arm, prospective, exploratory clinical study aiming to evaluate the efficacy and safety profile of sintilimab combined with anlotinib hydrochloride and platinum-containing dual-agent chemotherapy regimens in…
- Conditions
- Metastatic NSCLC, Recurrent NSCLC, Advanced Non-Small Cell Squamous Lung Cancer
- Trial name
- NCT04846452
- Testing
- Sintilimab + Anlotinib + Pemetrexed + Cisplatin or Carboplatin, Sintilimab + Anlotinib + Albumin Paclitaxel + Carboplatin
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University